CBAY:NSD-Cymabay Therapeu (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 4.08

Change

+0.05 (+1.24)%

Market Cap

USD 0.36B

Volume

0.62M

Avg Analyst Target

USD 10.00 (+145.10%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


CBAY Stock Forecast & Price:
Based on the Cymabay Therapeu stock forecasts from 3 analysts, the average analyst target price for Cymabay Therapeu is USD 10.00 over the next 12 months. Cymabay Therapeu’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Cymabay Therapeu is Very Bearish, which is based on 0 positive signals and 6 negative signals. At the last closing, Cymabay Therapeu’s stock price was USD 4.08. Cymabay Therapeu’s stock price has changed by +17.24% over the past week, +18.60% over the past month and +4.88% over the last year.

About Cymabay Therapeu (CBAY:NSD)

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-08-09 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Inc

+4.88 (+1.66%)

USD73.74B 29.01 20.60
MRNA Moderna Inc

-11.80 (-6.45%)

USD71.57B 5.79 4.08
REGN Regeneron Pharmaceuticals Inc

-8.48 (-1.34%)

USD68.73B 12.65 9.34
BNTX BioNTech SE

-12.09 (-7.14%)

USD40.37B 3.26 2.01
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
SGEN Seagen Inc

-2.73 (-1.53%)

USD32.89B 55.02 -46.79
RPRX Royalty Pharma Plc

+0.54 (+1.25%)

USD28.69B 41.21 16.21
ALNY Alnylam Pharmaceuticals Inc

-7.37 (-3.19%)

USD27.46B N/A -34.32
GMAB Genmab AS

-0.08 (-0.23%)

USD22.96B 73.23 6.37
BGNE BeiGene Ltd

-4.62 (-2.28%)

USD21.09B N/A -7.47

ETFs Containing CBAY

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 20.71% 91% A- 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 20.71% 91% A- 94% A
Trailing 12 Months  
Capital Gain 6.81% 87% B+ 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.81% 87% B+ 87% B+
Trailing 5 Years  
Capital Gain -38.74% 55% F 24% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -38.74% 55% F 23% F
Average Annual (5 Year Horizon)  
Capital Gain 3.41% 56% F 58% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.41% 55% F 53% F
Risk Return Profile  
Volatility (Standard Deviation) 91.33% 27% F 14% F
Risk Adjusted Return 3.73% 53% F 43% F
Market Capitalization 0.36B 65% D 52% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 3.08 36% F 30% F
Price / Cash Flow Ratio -5.18 63% D 70% C-
EV/EBITDA -2.37 65% D 71% C-
Management Effectiveness  
Return on Equity -85.28% 34% F 15% F
Return on Invested Capital -53.74% 50% F 19% F
Return on Assets -35.01% 31% F 10% F
Debt to Equity Ratio 37.85% 39% F 46% F
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 3.01 55% F 49% F
Short Percent 4.90% 44% F 34% F
Beta 0.67 77% C+ 76% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector